Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 5, 2004, Pages 260-266

  Langman, M J S ^a   Eichler, H G ^b,c   Mavros, P ^b   Watson, D J ^b   Kong, S X ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adverse event; Antihypertensive; Blood pressure; Clinical practice; COX 2 inhibitor; NSAID; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELECOXIB; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

EID: 2542450028     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42260     Document Type: Review

References (21)

1. August P, Oparil S 1999 Hypertension in women. J Clin Endocrinol Metab 84: 1862-1866
2. Berkson J 1946 Limitations of the application of 4-fold tables to hospital data. Biometr Bull 2: 47-53
3. Brater DC 2002 Renal effects of cyclooxygenase-2-selective inhibitors. J Pain Sympt Manag 23: S15-S20
4. Dilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U 2002 Effects of celecoxib and diclofenac on blood pressure, renal function and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 42: 985-994
5. Geba GP, Polis AB, Dixon ME, Dobbins TW, Rush JE, Weir MR 2001 Comparative blood pressure effects of rofecoxib, celecoxib and placebo in patients with osteoarthritis (OA): a randomized controlled trial. Ann Rheum Dis 60 (Suppl 1): 238 (abstract SAT0095)
6. Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A 2002 A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator nonselective nonsteroidal anti-inflammatory agents. Curr Med Res Opin 18: 82-91
7. Johnson AG, Nguyen TV, Day RA 1994 Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121: 289-300
8. Murray MD, Lazaridis EN, Brizendine E, Haag K, Becker P, Brater DC 1997 The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci 314: 80-88
9. Pope JE, Anderson JJ, Felson DTA 1993 A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153: 477-484
10. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M 1999 Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66: 76-84
11. Schnitzer TJ, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL 2003 An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther 25: 3162-3172
12. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K 2002 Comparison of rofecoxib, celecoxib and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72: 50-61
13. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC et al 2002 Consensus conference report: controversies in COX-2-selective inhibition. J Rheumatol 29: 1501-1510
14. Straus WL, Barlas S, Stever GJ, Brater DC 2001 A comparison of the clinical impact of rofecoxib vs. celecoxib on new onset hypertension. Arthritis Rheum 44 (Suppl 9): S317 (abstract 1589)
15. Whelton A, Maurath CJ, Verburg KM, Geis S 2000 Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7: 159-175
16. Whelton A, White WB, Bello AE, Puma JA, Fort JG 2002 Effects of celecoxib and rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90: 959-963
17. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB 2002 Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2-specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89: 425-430
18. Wolfe F, Michaud K, Zhao SZ, Burke TA, Pettitt D 2002 Toward an epidemiology of NSAID and COX-2-specific inhibitor equivalence. Arthritis Rheum 46 (Suppl 9): S336 (abstract 850)
19. Yocum DE, Nordensson KA 2001 Comparison of COX-2-specific nonsteroidal anti-inflammatory drugs (NSAIDs) to other agents in the treatment of arthritis in the clinical setting. Arthritis Rheum 44 (Suppl 9): S318 (abstract 1594)
20. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC 2002 Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Am J Manag Care 8 (Suppl 15): S392-400
21. Zhao S, Wentworth C, Burke T, Makuch R 2004 Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using Cox-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf (in press)